Transforming Autoimmune & Cancer Therapy

Forta Bio

Pioneering cell-specific DNA therapies that disrupt telomeres and activate immune responses. Offering targeted, safe, and effective treatments for autoimmune diseases and cancer.

Get in Touch

About Us

Forta Bio is a next-generation biotech company developing precision therapies that selectively eliminate disease-driving immune and cancer cells — without compromising healthy immunity.Our proprietary cell targeting 6tdGO DNA platform uses a dual mechanism of action to directly disrupt telomeres in specific TERT+ cells while activating the body’s immune response. This approach is uniquely suited for treating aggressive cancers and autoimmune diseases.We focus on high-burden, underserved conditions — particularly those affecting women and children — and pursue accelerated regulatory pathways.Backed by validated science from City of Hope and led by a team with 7+ INDs, 30+ pharma deals, and multiple biotech exits, Forta Bio is on a mission to bring smarter, safer, and more targeted therapies to patients who need them most.

Revolutionary Targeted Technology

Proprietary 6-Thio-DeoxyGuanosine Oligonucleotides (6tdGO) represent a paradigm shift

Selective Targeting: Leaves healthy cells untouched, avoiding major side effects
Action: Destroys harmful cancer and hyper-activated immune cells by disrupting their DNA
Immune Activation: Triggers the body’s natural defenses to help clear diseased cells
Pediatric-Safe: Designed to be gentle enough for children, while still highly effective
Platform approach: Can be easily modified to target different harmful cells, including multiple solid cancers and inflammatory conditions

The Team

Dr. Zoya Gluzman-Poltorak

Co-Founder & Chief Executive Officer

A biotech veteran with 25+ years of experience leading drug development in gene and cell therapy, genome editing, and targeted biologics. She has taken multiple programs from early research to the clinic, serving as lead on seven FDA INDs and overseeing development across immunology, oncology, hematology, neurology, rare diseases, and cardiology. She’s built and led cross-functional teams, secured over $250M in public and private funding, and managed key partnerships with NIH, DoD, BARDA, and research collaborators.

Dr. Valeria Povolotsky

Co-Founder & Chief Business Officer

Biotech and Pharma executive, ex-Roche / Genentech, Valeria has closed over 30 strategic partnerships and licensing deals. She brings deep expertise in business development, global partnering, pharma alliances, and strategic growth to biotech companies.

Dr. Marcin Kortylewski

Co-Founder & Scientific Lead

A renowned immunologist and oligonucleotide expert with 100+ publications and 20+ patents. He leads Forta Bio’s scientific direction, with prior innovative research leadership at City of Hope and co-founder roles in multiple biotech ventures.

Let’s Connect

For investment, partnerships, or media inquiries — reach out anytime.

A Smarter, Safer Approach to Treatment

Forta Bio develops DNA breakthrough medicines that target the actual drivers of autoimmune disease and cancer — without hurting healthy immune cells. Our therapies are precise, well-tolerated, and designed for people who don’t respond to current options.